<DOC>
	<DOCNO>NCT00711386</DOCNO>
	<brief_summary>To determine safety , tolerability Pharmacokinetics GSK706769</brief_summary>
	<brief_title>GSK706769 Repeat Dose Study</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Healthy determine responsible physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Male female 18 50 year age . A female subject eligible participate nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) include female : Is premenopausal documented bilateral tubal ligation , bilateral oophorectomy ( removal ovary ) hysterectomy , Is postmenopausal defined 12 month spontaneous amenorrhea . A follicle stimulate hormone ( FSH ) level perform confirm postmenopausal status . For study , FSH level &gt; 40 mlU/ml confirmatory . Females hormone replacement therapy ( HRT ) whose menopausal status doubt , HRT discontinue 2 week subject rescreened , HRT suppress FSH . Male subject must agree use one contraception method list Section 8.1 . This criterion must follow time first dose study medication 14 day last dose study medication . Body weight ³ 50 kg men ³ 45 kg woman BMI within range 18.531.0 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . The subject positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive test HIV antibody . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 14 drinks/week men &gt; 7 drinks/week woman . One drink equivalent ( 12 g alcohol ) = 5 ounce ( 150 ml ) wine 12 ounce ( 360 ml ) beer 1.5 ounce ( 45 ml ) 80 proof distil spirit . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . This include subject history know suspected sulfa relate hypersensitivity . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive serum urine hCG test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . If heparin use PK sample , subject history sensitivity heparin heparininduced thrombocytopenia enrol . Has history regular use tobacco nicotinecontaining product within 3 month prior screen . Consumption grapefruit grapefruit juice 7 day prior first dose study medication last pharmacokinetic sample . Subjects preexist condition interfere normal gastrointestinal anatomy motility , hepatic and/or renal function , could interfere absorption , metabolism , and/or excretion study drug . Subjects history cholecystectomy exclude . Exclusion criterion screen per protocol . The subject 's systolic blood pressure outside range 90140mmHg , diastolic blood pressure outside range 4590mmHg heart rate outside range 50100bpm female subject 45100 bpm male subject . History/evidence symptomatic arrhythmia , angina/ischemia , coronary artery bypass graft surgery percutaneous transluminal coronary angioplasty clinically significant cardiac disease . History/evidence clinically significant pulmonary disease . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , direct bilirubin creatinine value great upper limit normal . A single repeat allow eligibility determination . History significant renal hepatic disease . Exclusion Criteria 24Hour Screening Holter per protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>GSK706769 ,</keyword>
	<keyword>CCR5</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>